SERES THERAPEUTICS, INC.

• TRUSTEES OF BOSTON UNIVERSITY

  UEI THL6A6JLE1S7

  $895.7K

  Subcontractor to this prime · 1 sub-award · latest Sep 15, 2025

  • Office of Assistant Secretary for Preparedness and Response
  • “SERES IS DEVELOPING A NOVEL LIVE BIOTHERAPEUTIC PRODUCT (LBP) OF HUMAN COMMENSAL BACTERIA FORMULATED FOR ORAL LIQUID DELIVERY, TO ADDRESS THE UNMET NEED FOR PREVENTION OF GUT-SEEDED AMR INFECTION IN THE MEDICAL ICU. INFECTIONS WITH PATHOGENIC (OFTEN MULTIDRUG RESISTANT, MDR) BACTERIA ARE THE LEADING CAUSE OF MORTALITY IN THE MEDICAL INTENSIVE CARE UNIT (ICU), CAUSING UP TO 9 DEATHS FOR EVERY 100 ICU PATIENTS ADMITTED (VINCENT, 2009). MOST PATIENTS ARE ADMITTED TO THE MEDICAL ICU WITH A KNOWN OR SUSPECTED INFECTION (I.E., SEPSIS) BUT, WITH TARGETED OR EMPIRIC ANTIBIOTICS, MOST RECOVER FROM THIS INITIAL INFECTION. WHAT CAUSES DEATHS—AND WHAT THIS PROJECT PROPOSES TO PREVENT—ARE THE SECONDARY, HEALTHCARE- ASSOCIATED INFECTIONS THAT FREQUENTLY DEVELOP DURING THE PROLONGED RECOVERY FROM SEPSIS. A NOVEL APPROACH THAT ADDRESSES BOTH GUT COLONIZATION AND SUBSEQUENT TRANSLOCATION BY E. COLI AND OTHER GUT SEEDED PATHOGENS COULD PREVENT A SIGNIFICANT PROPORTION OF THESE INFECTIONS. IF GUT COLONIZATION AND TRANSLOCATION BY E. COLI COULD BE AMELIORATED BY A LBP SUCH AS SER-155, A LARGE PROPORTION OF THESE INFECTIONS COULD BE PREVENTED. SER-155 IS CURRENTLY IN CLINICAL DEVELOPMENT AND HAS BEEN EVALUATED IN ALLOGENEIC HCT PATIENTS. DATA FROM OUR PHASE 1B STUDY SUPPORTS THE SAFETY AND EFFICACY OF SER-155 IN PREVENTING INFECTION IN IMMUNE COMPROMISED, HOSPITALIZED PATIENTS. THE PROPOSED WORK WILL EXTEND THESE FINDINGS BY DEVELOPING A LIQUID FORMULATION OF SER-155 (“SER-155-LF"), A NECESSARY STEP IN THE MEDICAL ICU AS PATIENTS ARE COMMONLY INTUBATED WITH NARROW-CALIBER GASTRIC OR DUODENAL FEEDING TUBES, PLACED FOR THE DELIVERY OF MEDICATIONS AND ENTERAL NUTRITION. UPON SUCCESSFUL DEVELOPMENT OF A LIQUID FORMULATION WHICH IS SUITED FOR DELIVERY IN THE ICU VIA NG TUBE, THE PROPOSED WORK PLAN WILL NEXT FOCUS ON GMP MANUFACTURING OF SER-155-LF FOR CLINICAL STUDY AND PREPARATION OF AN EARLY PHASE TRIAL IN ICU PATIENTS WITH A PRIMARY OUTCOME OF SAFETY AND ENGRAFTMENT, EXPLORATORY ENDPOINTS”

No reported sub-awards as a prime contractor.

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.